CSCIF (Cosciens Biopharma) Moat Score: 2/10 (As of Jun. 25, 2026)


CSCIF Cosciens Biopharma Inc CSCIF
62 GF Score
Price $1.99
GF Value $2.36
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Moat Score?

Cosciens Biopharma CSCIF -5.24% 62 Moat Score is 2 as of Jun. 25, 2026. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.36 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,405 Biotechnology companies, Cosciens Biopharma ranks better than 58.15% on this metric.

Cosciens Biopharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Cosciens Biopharma has No Moat: Cosciens Biopharma Inc has limited market presence and lacks significant intellectual property or regulatory advantages. The company does not demonstrate strong brand loyalty or cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cosciens Biopharma might have No Moat - Very weak/transient advantages.

Cosciens Biopharma  (OTCPK:CSCIF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cosciens Biopharma Moat Score Related Terms

CSCIF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Moat Score falls into.


CSCIF
62GF Score
Cosciens Biopharma Inc CSCIF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Cosciens Biopharma (CSCIF) has a Moat Score of 2 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cosciens Biopharma ranks #588 out of 1405 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Cosciens Biopharma's Moat Score too high?
Cosciens Biopharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Cosciens Biopharma's value of 2 is 0% at this industry median. Based on the distribution chart, Cosciens Biopharma ranks #588 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #588 out of 1405 companies for Moat Score. This puts Cosciens Biopharma in the upper half of its industry. The industry median Moat Score is 2.00. Cosciens Biopharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.36, compared to a current price of $1.99 — trading 15.7% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Moat Score is 2 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $1.99 is trading 15.7% below its estimated GF Value™ of $2.36. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Moat Score: 2
  • GF Value™: $2.36 vs. price of $1.99 (15.7% below fair value)
  • GF Score™: 62/100 with 6 warning signs
  • Industry Position: 0% at the Biotechnology median (#588 of 1405)

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score

Get the complete analysis for CSCIF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price
$2.36
GF Value